Novozymes Biopharma has entered a research agreement with EpiVax, Inc. for the development of a potential treatment for autoimmune diseases. The research will involve linking EpiVax’s Tregitope (T regulatory epitopes) immune-modulating therapy for the treatment of Type 1 diabetes to Novozymes’ Albufuse half-life extension platform, with the goal of enhancing its pharmacokinetic and pharmacodynamic properties.
“Novozymes is delighted to announce a research agreement with EpiVax in the key area of autoimmune diseases treatment,” said Dave Mead, business development director at Novozymes Biopharma. “The two technologies jointly have a role to play in a wide-range of treatments for autoimmune diseases. By taking EpiVax’s pioneering therapy and combining it with Novozymes’ versatile and clinically demonstrated Albufuse technology, along with the unparalleled expertise of our R&D scientists, we will work together to move the treatment to the next stage in its development.”
Dr. Annie De Groot, chief executive officer at EpiVax, Inc. said, “Novozymes’ proven solutions, technical expertise, and reputation as a reliable partner makes it the ideal company for us to work with as we move our Tregitope immune-modulating technology closer to clinical trials. By bringing together our unique knowledge and experience in our respective fields, we look to develop an industry-changing technology that will make significant advancements in treating patients with autoimmune diseases.”
Novozymes, EpiVax To Develop Diabetes Treatment
Published February 13, 2013
blog comments powered by Disqus